Medical Device Advertising and Labelling Compliance in Jordan

1. Key takeaways

The JFDA’s compliance review of labels and advertising is continuous and does not end when a product obtains registration. The GRZAN conclusion is that advertising compliance in Jordan is an extension of registration compliance: promotional content must remain consistent with the intended use, indications, warnings and precautions approved in the registration dossier, and it must stay consistent over the whole life of the approval, not only on the day it is granted. Any later change to indications or warnings flows through to the promotional material as well, whether or not the marketing team is aware of the change.

The second takeaway: promotion directed at the public is the high-risk zone. For products that enter retail channels or are used by patients, promotional material is subject to stricter review standards and must also meet the Arabic language requirements, because the audience cannot be assumed to read professional documentation in English. Retail-facing claims are also the ones most likely to be read literally by patients, which is precisely why the review standards tighten at that point.

The third takeaway: advertising compliance is linked to market surveillance. JFDA market surveillance includes review of the ongoing compliance of labels and advertising, and non-compliant promotion triggers the inspection and penalty procedures rather than being handled as a separate, softer track. In practical terms, an overclaiming brochure can lead an inspector to the same premises that the sampling programme would visit anyway.

2. Legal basis

Clause numbers are subject to the Arabic originals published in the Jordanian Official Gazette and by the JFDA. Read together, the three instruments cover what may be promoted, how non-compliant promotion is enforced, and what the label itself must satisfy while the product circulates.

3. Expert insights

Insight one: consistency is the first principle of advertising compliance. The indications, performance claims and target populations in promotional content must match what the JFDA approved in the registration dossier. Claims that go beyond the approved scope are the most common type of violation, and they are also the easiest to avoid, since the approved content already exists in the dossier and only needs to be respected. A dossier-aligned review loop is therefore cheaper than any penalty or re-approval effort that follows a violation.

Insight two: the language requirement extends to promotional material. Products aimed at retail channels or patients must use Arabic or be bilingual in Arabic and English, and this requirement applies equally to promotional material and patient education material directed at the local market. Companies that translate their labels but leave brochures and web pages in English only remain exposed on this point.

Insight three: the standards for professional and public channels differ. Scientific promotion directed at hospital departments and professionals, and mass-market promotion directed at patients, are reviewed with different intensity in Jordan. GRZAN recommends establishing separate review processes for two categories of material, a single process calibrated to one audience will systematically miss the risks of the other. What is acceptable scientific nuance before a clinician may read as an overclaim when printed in a patient leaflet.

Insight four: digital channels are regulated too. Product descriptions on corporate websites, social media and e-commerce pages fall within the scope of advertising. Companies frequently overlook compliance review of these digital channels, even though they are often the most visible material a company publishes and the easiest to update without internal control. Every web edit is a publication in the regulatory sense, even when no one in the regulatory function sees it.

Insight five: violations are handled through the inspection and penalty procedures. Law No. 33 (2017) provides the procedural basis for JFDA inspections and penalties at premises in the circulation chain, and advertising violations are generally dealt with under the framework of that law. The consequence is that promotional non-compliance is not treated as a marketing matter but as a circulation matter subject to inspection.

4. Practical recommendations

First, establish a consistency review for promotional content. Before any external material is released, compare it item by item against the approved content of the registration dossier, so that overclaiming is caught before publication rather than after.

Second, set up separate review processes for professional and public material. Public material is held to stricter standards and must also satisfy the Arabic language requirements.

Third, bring digital channels into the compliance scope. Product descriptions on corporate websites, social media and e-commerce pages should be reviewed together with the rest, with the same consistency standard applied.

Fourth, specify local review duties for promotional material in the AR agreement. Having a local gatekeeper who is familiar with JFDA expectations reduces the probability of violations, because local reviewers can catch tone and wording issues that an overseas marketing team cannot see.

5. Verification checklist

• □ Consistency review of all promotional material against the approved dossier content is complete
• □ Public-facing material satisfies the Arabic or Arabic-English bilingual requirement
• □ Separate review processes exist for professional-channel and public-channel material
• □ Corporate websites, social media and e-commerce pages are included in the compliance review scope
• □ Local review duties for promotional material are specified in the AR agreement
• □ A mechanism exists for re-reviewing promotional material after regulatory changes
• □ Cited clause numbers are verified against the Arabic originals of the Official Gazette

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team manages adverse event reporting and recall coordination with the JFDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com